Ironwood Pharmaceuticals, Inc. Class A IRWD
NASDAQ · United States · Health Technology
$3.76-0.21 (-5.29%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
BOSTON, September 03, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET.
Moby summary of Ironwood Pharmaceuticals, Inc.'s Q2 2026 earnings call
Ironwood Pharmaceuticals reported past second-quarter 2026 results showing sales of US$113.04 million versus US$85.24 million a year earlier, with net income rising to US$51.29 million from US$23.6 million and earnings per share from continuing operations doubling to US$0.31 basic and US$0.31 diluted. For the first half of 2026, the company grew sales to US$219.55 million from US$126.38 million and shifted from a loss to a US$92.06 million profit, prompting management to raise full-year 2026...
Ironwood Pharmaceuticals Inc (IRWD) raises full-year 2026 outlook on robust LINZESS performance and promising apraglutide data.
BOSTON, August 06, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance.
BOSTON, July 30, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) using conference ID number and event passcode 3647053. To access the webcast, please visit the Investors & Media section of Ironwood’s website at www.ironwood
BOSTON, July 14, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs reporting to
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.